Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated:  3/8/2016
Providence Portland Medical Center
mi
from
Portland, OR
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated: 3/8/2016
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated:  3/8/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated: 3/8/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated:  3/8/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Status: Enrolling
Updated: 3/8/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Northern Arizona Hematology/Oncology Associates, P.C. Dept. of No. AZ Hem-Onc
mi
from
Flagstaff, AZ
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Northern Arizona Hematology/Oncology Associates, P.C. Dept. of No. AZ Hem-Onc
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
City of Hope National Medical Center Regulatory Document
mi
from
Duarte, CA
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
City of Hope National Medical Center Regulatory Document
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(4)
mi
from
Duarte, CA
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(4)
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of California at Los Angeles GI Oncology Program
mi
from
Los Angeles, CA
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of California at Los Angeles GI Oncology Program
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Stanford University Medical Center Stanford Cancer Center
mi
from
Stanford, CA
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Stanford University Medical Center Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of Colorado Dept of Univ. of Colorado
mi
from
Aurora, CO
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of Colorado Dept of Univ. of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
mi
from
Greenwood Village, CO
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Washington Hospital Center Wash Hospital
mi
from
Washington,
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Washington Hospital Center Wash Hospital
mi
from
Washington,
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Ocala Oncology Center Dept. of Ocala Oncology Center
mi
from
Ocala, FL
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Ocala Oncology Center Dept. of Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Kootenai Medical Center Dept.ofKootenai Med.Ctr.
mi
from
Coeur d'Alene, ID
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Kootenai Medical Center Dept.ofKootenai Med.Ctr.
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Northwestern University Clinical Research Office (2)
mi
from
Chicago, IL
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Northwestern University Clinical Research Office (2)
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Dana Farber Cancer Institute Centerfor Sarcoma&BoneOncology
mi
from
Boston, MA
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Dana Farber Cancer Institute Centerfor Sarcoma&BoneOncology
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(6)
mi
from
Ann Arbor, MI
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(6)
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Minnesota Oncology Hematology, P.A. SC
mi
from
Minneapolis, MN
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Minnesota Oncology Hematology, P.A. SC
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Mayo Clinic - Rochester Division of Hematology
mi
from
Rochester, MN
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Mayo Clinic - Rochester Division of Hematology
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
New York Oncology Hematology, P.C. NYOH@AlbanyMedicalCenter(2)
mi
from
Troy, NY
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
New York Oncology Hematology, P.C. NYOH@AlbanyMedicalCenter(2)
mi
from
Troy, NY
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
New York Oncology Hematology, P.C. NYOH Amsterdam
mi
from
Troy, NY
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
New York Oncology Hematology, P.C. NYOH Amsterdam
mi
from
Troy, NY
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of Pennsylvania Medical Center CAMN107G2301
mi
from
Philadelphia, PA
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of Pennsylvania Medical Center CAMN107G2301
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Vanderbilt Univeristy Ingram Cancer Center
mi
from
Nashville, TN
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Vanderbilt Univeristy Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Texas Oncology, P.A. Tex Onc (2)
mi
from
Bedford, TX
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Texas Oncology, P.A. Tex Onc (2)
mi
from
Bedford, TX
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Texas Oncology, P.A. Wichita Falls
mi
from
Dallas, TX
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Texas Oncology, P.A. Wichita Falls
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3)
mi
from
Dallas, TX
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3)
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of Texas/MD Anderson Cancer Center Dept. of MD Anderson (13)
mi
from
Houston, TX
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of Texas/MD Anderson Cancer Center Dept. of MD Anderson (13)
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
mi
from
Tyler, TX
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(3)
mi
from
Salt Lake City, UT
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(3)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (2)
mi
from
La Jolla, CA
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (2)
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  3/9/2016
Novartis Investigative Site
mi
from
Caba,
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 3/9/2016
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma
Status: Enrolling
Updated:  3/9/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma
Status: Enrolling
Updated: 3/9/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated:  3/9/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated: 3/9/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated:  3/9/2016
Emory University/Childrens Healthcare of Atlanta
mi
from
Atlanta, GA
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated: 3/9/2016
Emory University/Childrens Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated:  3/9/2016
Columbia University
mi
from
New York, NY
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated: 3/9/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated:  3/9/2016
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated: 3/9/2016
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated:  3/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
Status: Enrolling
Updated: 3/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver
Status: Enrolling
Updated:  3/9/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver
Status: Enrolling
Updated: 3/9/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers
Status: Enrolling
Updated:  3/9/2016
Eskenazi Hospital
mi
from
Indianapolis, IN
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers
Status: Enrolling
Updated: 3/9/2016
Eskenazi Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers
Status: Enrolling
Updated:  3/9/2016
Richard L. Roudebush VA Medical Center
mi
from
Indianapolis, IN
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers
Status: Enrolling
Updated: 3/9/2016
Richard L. Roudebush VA Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers
Status: Enrolling
Updated:  3/9/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers
Status: Enrolling
Updated: 3/9/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients
Screening for Gynecologic Cancers Among Women With Hereditary Non-Polyposis Colon Cancer (HNPCC)
Status: Enrolling
Updated:  3/10/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients
Screening for Gynecologic Cancers Among Women With Hereditary Non-Polyposis Colon Cancer (HNPCC)
Status: Enrolling
Updated: 3/10/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Wellstar Cancer Research
mi
from
Marietta, GA
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Wellstar Cancer Research
mi
from
Marietta, GA
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Providence Medical Group
mi
from
Terre Haute, IN
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Providence Medical Group
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Norton Cancer Institute
mi
from
Louisville, KY
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials